Company: JUNS
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001493152-25-023603
Chunk: 145

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-11-14
Form: 10-Q
Item: Item 1
Chunk 145
---
 to this interest.

The
Company has entered service agreements with firms in Hong Kong to accelerate product development in South-East Asia. These agreements
aim to leverage local expertise and networks to facilitate market entry and potential out-licensing deals. The Company entered into an
agreement with Dominant Treasure Health to expand its business development in China, Malaysia, and Singapore, aiming to penetrate the
large and challenging Asian market.

24

In
March 2025, the Company announced that it had entered into a partnership with Aquanova AG to develop a series of nutritional products
targeting longevity, aging and healthspan. The first three products, which will focus on the concept of “Beauty from Within”,
are slated to hit the market in the third quarter of 2025 through a Direct-to-Consumer model. The Company will form a wholly-owned subsidiary
to focus on the consumer market and will market its products on a to-be-developed website targeting the US market, along with social
media marketing. Internationally, the Company is focusing on partners who can market and accelerate sales, with an initial focus on the
Asian region.

Beginning
in the second quarter of 2025, the Company began accepting pre-orders for Nugevia, a dietary supplement expected to be commercially available
beginning in Fall 2025. Once launched, the Company expects to generate product sales through (i) direct-to-consumer (“DTC”)
e-commerce, including one-time purchases and auto-ship subscriptions, (ii) third-party online marketplaces, and (iii) wholesale/distributor
channels.

During
2025, the Company initiated a transition toward two operating activities: (i) production and sale of premium nutritional supplements
(marketed under the Nugevia® brand) and (ii) pharmaceutical operations focused on the development of drug candidates.

Financial
Position

The
accompanying condensed consolidated financial statements of the Company have been prepared in conformity with generally accepted
accounting principles in the United States of America (“U.S. GAAP”). U.S. GAAP contemplates the
continuation of the Company as a going concern. The Company has had no revenues from product sales since inception and incurred a
net loss of $6,069,866 and had negative cash flows of operations totaling $3,045,713 for the nine months ended September 30, 2025,
and a cumulative net loss since inception totaling $32,091,995.

In
management’s opinion, these conditions raise substantial doubt about the